Buy & Sell Alnylam Pharmaceuticals, Inc. (ALNY) – Alnylam Pharmaceuticals, Inc. Price Today
Aura AI Summary
Key Stats
- $39.18BMarket Cap
- HealthSector
- -16.08%3M Drawdown
- $37.44BEnterprise Value
- -Dividend Yield
- 40 daysTypical Hold Time
Alnylam Pharmaceuticals, Inc. (ALNY) is currently valued at a market capitalization of $39.18B, with an enterprise value of $37.44B. Over the past 52 weeks, Alnylam Pharmaceuticals, Inc. has traded between a low of $283.4 and a high of $491.22, highlighting its annual price range. Over the past three months, Alnylam Pharmaceuticals, Inc. has recorded a drawdown of -16.08%, reflecting recent price volatility. On average, investors hold Alnylam Pharmaceuticals, Inc. for approximately 40 days, indicating typical investor behavior on the platform.
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Most Recent News
Bond market signals Fed rate hike likely by December 2026, ending AI rally surge.
The bond market now signals a Federal Reserve rate hike is more likely than not by December 2026, reversing earlier expectations of rate cuts. This shift comes amid strong economic data, including rising retail sales and inflation pressures driven by...
Trump demands a real 20-year nuclear ban from Iran, rejects favors from China on Hormuz Strait issue.
President Donald Trump insisted on a genuine 20-year nuclear activity ban from Iran and dismissed Iran's recent proposal as unacceptable. He emphasized that the U.S. does not seek favors from China regarding reopening the Strait of Hormuz, asserting ...
U.S. court rejects FTC's attempt to impose severe sanctions on Cliq over fraud claims
A U.S. District Court has dismissed the Federal Trade Commission's (FTC) accusations against Cliq, a financial technology company, clearing it of fraud after a three-year investigation. The court rejected the FTC's demands for harsh penalties, includ...
